Board of Directors

Neil FlanzraichExecutive Chairman of Cantex Pharmaceuticals, Inc.
Former Vice Chairman and President of IVAX Corporation

Mr. Flanzraich brings to Alzheon more than 30 years of executive leadership, operations and legal experience with pharmaceutical and life sciences companies.  Mr. Flanzraich was an early investor in Alzheon and served in the role of Chief Business Officer of Alzheon as a consultant to the company from February to May 2018.

Mr. Flanzraich is the Executive Chairman of Cantex Pharmaceuticals, Inc., a privately-owned biotech company, which is developing drugs for cancer.  Previously, he was Cantex’s Chief Executive Officer.  Mr. Flanzraich served as Vice Chairman and President of IVAX Corporation, an international pharmaceutical company, for over seven years, prior to its sale in 2006 to TEVA Pharmaceutical Industries, Ltd. for an enterprise value of $10 billion.  Prior to his tenure at IVAX, Mr. Flanzraich served as Chairman of the Life Sciences Legal Practice Group of Heller Ehrman LLP, a law firm.  Previously Mr. Flanzraich worked at Syntex Corporation, an international pharmaceutical company, where, as the Senior Vice President, and a member of both the Corporate Operating and Corporate Executive Committees, he made major contributions to the value of the company, which was acquired by Roche in 1994 for $5.3 billion.

Mr. Flanzraich was an early investor and member of the board of directors of Chipotle Mexican Grill, Inc. (NYSE: CMG), and is currently its lead independent director.  Mr. Flanzraich was the lead independent director of Equity One, Inc. (NYSE: EQY), prior to its acquisition by Regency Centers Corporation in 2017.  He was an independent director of Continucare Corporation (NYSE: CNU), a company with primary care centers, from 2002 to its sale in 2011.  Mr. Flanzraich received an AB from Harvard College and a JD from Harvard Law School.

We believe that Mr. Neil Flanzraich is qualified to serve on our board of directors because of his business expertise and extensive experience in the pharmaceutical and biotechnology industries.

Noel DunnExecutive Chairman and Director, ERO Copper

Mr. Dunn serves as the Executive Chairman and as a director of ERO Copper.  Mr. Dunn has 25 years’ experience in the investment banking industry, primarily with Goldman Sachs managing a capital underwriting business in London. In later years he worked with Bear Stearns and JP Morgan as a leader of their respective investment banking practices in mining and metals.  Mr Dunn is a former director of Pan American Silver and Pretivm Resources.  Prior to forming Ero Resource Partners LLC, he was a Managing Director of Liberty Mining & Metals LLC, a subsidiary of Liberty Mutual Investments.  Mr. Dunn holds a Master of Arts degree from the University of Edinburgh and a Master of Science degree from the University of Durham.

Jordan HellerManaging Director and Partner, Beacon Pointe Wealth Advisors

Jordan Heller CFA, CFP®, CPA is a Managing Director and Partner of Beacon Pointe Wealth Advisors having founded Heller Wealth Management prior to merging it with Beacon Pointe. Prior to Beacon Pointe, Mr. Heller was a partner of The Schonbraun McCann Group (SMG), currently FTI Consulting, as well as managing partner of SMG’s wealth management subsidiary. Prior to joining the Schonbraun McCann Group, Mr. Heller spent four years at American Economic Planning Group (AEPG) in a similar capacity. Prior to entering the wealth management industry in 2000, Jordan spent 15 years on Wall Street heading the Real Estate and Real Estate Finance Securities Research group at some of the country’s leading investment houses, including Merrill Lynch, Salomon Brothers and CIBC. During this time, Jordan played a leading role in the rebirth of the modern-day REIT industry. He began his career in public accounting, joining Price Waterhouse in 1982, and moving to Wall Street in 1985. Jordan has extensive investment banking, advisory, and research experience.

Jordan serves on the Board of Directors of Bed Bath and Beyond and served on the board of Equity One until it’s sale to Regency Centers in 2017. He is a member of the Board of Trustees of the New York College of Podiatric Medicine, is a member of the Investment Management Consultants Association, Association for Investment Management and Research and the New York Society of Security Analysts. Jordan obtained his undergraduate degree from Bentley University in Waltham, MA, with a B.S. in Accountancy.

We believe that Mr. Jordan Heller is qualified to serve on our board of directors because of his business expertise and extensive investment experience.

Diane Jorkasky Alzheon Board of DirectorsExpert Consultant, NDA Partners

Diane K. Jorkasky, MD FACP is a highly regarded medical scientist with a broad background across research and all phases of clinical development in multiple therapeutic areas. Diane currently serves as an Expert Consultant at NDA Partners – a life sciences management consulting and contract development organization. Most recently Diane was Chief Medical Officer, Head of Development and Executive Vice President of Complexa Inc. (Berwyn, PA) whose nitrofatty acid signaling technology is being developed for rare diseases of the kidney and cardiopulmonary systems. Additionally, Diane served as Chief Medical Officer at Endo Pharmaceuticals (Chadds Ford, PA), and Aileron Therapeutics (Cambridge, MA) where she guided the development of stapled peptides in oncology. At Pfizer Global R&D (New London, CT), she served as Vice President of Global Clinical Research Operations, responsible for all exploratory development, clinical pharmacology (phase 1-4), and translational medicine. Diane led the Pfizer International Clinical Research Units which received certification by American Accreditation for Human Rights Protection Policies for their clinical research process, the first in industry or academia to achieve such a recognition. Previously, she was Vice President of Clinical Research at SmithKline Beecham, and Chief of Nephrology at Presbyterian-Penn Medical Center in Philadelphia. Dr. Jorkasky is a member of the Connecticut Academy of Science and Technology and has been recognized by the Connecticut Women’s Hall of Fame for her scientific leadership and mentoring of young women. Dr. Jorkasky is board certified in internal medicine, nephrology and clinical pharmacology, having received her medical degree from University of Pennsylvania. She has been on the faculties of UCSF, Yale, Penn and Uniformed Service of Health Sciences Medical Schools, has published on over 100 peer review articles, and is a Woodrow Wilson Visiting Fellow.

David Nikodem AlzheonAlly Bridge Group

David P. Nikodem, Ph.D. was nominated to our board of directors by ABG II-Alzheon Limited, one of our shareholders, and has been a member of our board of directors since December 2014. Dr. Nikodem has also served as a senior representative of Ally Bridge Group, or ABG, and serves on the boards of several of ABG’s U.S.-based biopharmaceutical companies. From December 2010 to September 2013, Dr. Nikodem served as Portfolio Manager at Exane Asset Management, an asset management company, where he managed a global healthcare fund.

Dr. Nikodem received his Ph.D. in molecular biology from Georgetown University.

We believe that Dr. Nikodem is qualified to serve on our board of directors because of his investment experience and knowledge of the pharmaceutical and biotechnology industries.

Martin Tolar AlzheonFounder, President & Chief Executive Officer, Alzheon, Inc.

Prior to founding Alzheon in June 2013, Dr. Tolar has held executive positions in life sciences companies, where he has successfully established and grown new companies, business areas and product opportunities. Dr. Tolar served as President & CEO of Knome, Inc., where he led the development of human genome interpretation systems and services for academic, pharmaceutical and clinical clients, as President & CEO at NormOxys, Inc., where he built the business for novel cancer therapeutics, and as Chief Scientific Officer and Chief Business Officer at CoMentis, Inc., where he developed the first clinical-stage beta secretase inhibitor platform for Alzheimer’s disease and negotiated a collaboration with a potential value of $1.1 billion with Astellas Pharma in 2008. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, where he was instrumental in a wide range of business transactions, including acquisition of Rinat Neuroscience for $500 million in 2006, and directed programs through all stages of clinical development and FDA approval including NDA filings.

During his academic career, Dr. Tolar served as an Assistant Professor in the Department of Neurology at Yale University School of Medicine, where he focused on movement disorders. Dr. Tolar trained in Neurology at the Boston Medical Center, received a Ph.D. in Neuroscience for his work on the role of apolipoprotein E in Alzheimer’s disease, and published many scientific publications in the area of neuroscience and neurodegenerative disorders. Dr. Tolar received his M.D. from Charles University in Prague, where as a medical student he helped organize and lead the Velvet Revolution that toppled the communist regime in the former Czechoslovakia in November 1989.

Dr. Tolar serves on business and scientific boards including the Alzheimer’s Drug Discovery Foundation, the Alzheimer Foundation and Advance Healthcare Management Institute.

Dr. Tolar was recognized as one of the Top 100 Most Influential People in the world of drug development and manufacture by The Medicine Maker Magazine’s Power Lists for 2016, 2017, 2018 and 2019.

We believe that Dr. Tolar is qualified to serve on our board of directors because of his scientific expertise and extensive experience in the pharmaceutical and biotechnology industries.